Actively Recruiting
Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
Led by Peking Union Medical College Hospital · Updated on 2025-03-18
440
Participants Needed
1
Research Sites
258 weeks
Total Duration
On this page
Sponsors
P
Peking Union Medical College Hospital
Lead Sponsor
P
Peking University Cancer Hospital & Institute
Collaborating Sponsor
AI-Summary
What this Trial Is About
The most common external beam radiotherapy fractionation scheme for cervical cancer is 45-50.4 Gy delivered in 25-28 fractions. However, prolonged treatment duration can lead to insufficient availability of medical resources. We hope to assess the safety and efficacy of moderated hypofractionated online adaptive radiotherapy in combination with brachytherapy in patients with cervical cancer in a multicenter study.
CONDITIONS
Official Title
Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- The patient voluntarily consents and signs informed consent at least 30 days before enrollment
- Age between 18 and 75 years
- Diagnosed with FIGO stage IB-IIIB cervical cancer or stage IIIC1 with lymph node metastasis 2 cm or less, excluding common iliac lymph node metastasis
- Pathological diagnosis of squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
- Receiving concurrent weekly cisplatin chemotherapy with or without immunotherapy
- Able to undergo brachytherapy
- ECOG performance status of 0-1 and can tolerate lying flat for 30 minutes
You will not qualify if you...
- Prior cervical cancer surgery except pelvic lymphadenectomy, pelvic lymph node dissection, or cervical conization
- FIGO stage IA, IIIC2, IVA, or IVB cervical cancer
- FIGO stage IIIC1 with lymph nodes larger than 2 cm or common iliac lymph node metastasis
- History of abdominal or pelvic radiotherapy
- Pregnant or breastfeeding women
- Active infections or fever
- Serious health conditions affecting trial compliance such as unstable heart disease, kidney disease, chronic hepatitis requiring treatment, poorly controlled diabetes, or mental disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking Union Medical College Hospital
Beijing, China
Actively Recruiting
Research Team
Z
Zheng Zeng, MD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here